arrow
M

Manuel J. Rial

ciber of respiratory diseases
H指数:17
被引数:1,056

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stability of Asthma Biomarkers Over a Two-year Period Using Three Distinct Classifications in the MEGA Cohort

哮喘生物标志物在两年期间内的稳定性:MEGA队列中三种不同分类的应用

2025-07-050
PRE
FEV1Q as a Predictive Metric for Asthma Outcomes

FEV1Q作为预测哮喘结局的指标

2025-03-010
PRE
Global Lung Initiative as Diagnostic Criteria in Asthma-COPD Overlap Syndrome: Prevalence and Disease Characterization in a Real-Life Asthma Cohort

全球肺倡议作为哮喘-COPD重叠综合征的诊断标准: 现实生活中哮喘队列的患病率和疾病特征

2024-06-190
OA
Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee

更新的全身性过敏反应分级系统: 世界过敏组织过敏反应委员会和过敏原免疫治疗委员会的联合声明

2024-03-0115
OAAI
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

在严重哮喘患者的现实队列中,使用不同标准比较奥马珠单抗和Anti-IL-5/IL-5R的长期反应和缓解

2024-01-014
OA
Reply to Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies

对嗅觉功能和生物治疗的回复: 对现有现实生活研究的评论

2023-12-130
OA
Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

西班牙哮喘队列中与工作相关的哮喘的处置: 在职和退休工人之间哮喘严重程度的比较

2023-11-014
OAAI
Global disparities in availability of epinephrine auto-injectors

肾上腺素自动注射器可用性的全球差异

2023-10-017
OAAI
The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

新的ERS/ATS 2022支气管扩张剂反应建议: 在哮喘队列中与以前版本的比较

2023-09-014
OAAI
Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma
2023-07-272
OA
Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

哮喘患者的急性加重在很大程度上取决于共病的存在。

2023-07-276
OA
Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

使用聚类分析在西班牙大型队列研究中识别哮喘表型

2023-04-016
OA